Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

KURA

Phase 1b

Ziftomenib + venetoclax/azacitidine

AML (Acute Myeloid Leukemia) (NPM1-m and KMT2A-r)

H2 2025

KOMET-007 trial. 1/30/24- Initial data from 20 patients. Enrollment at 400 mg dose ongoing. 12/9/24- Interim data reported and presented at ASH '24. 2/26/25- Present prelim data at a medical meeting in H2 2025.

Data readout

JSPR

Phase 1b/2a

Briquilimab

Asthma

H2 2025

ETESIAN Study. 12/2/24- First patient dosed. Initial data in H2 2025.

Data readout

CRVS

Phase 1b/2

Ciforadenant (A2AR inhibitor) +/- ipilimumab and nivolumab

RCC (renal cell carcinoma)

2025

Collab w/ KCRC. 11/7/23- Ph1b completed and enrollment ongoing in Ph2 portion. Positive Ph1b/2 interim data. Next clinical update in 2025.

Data Readout

RVMD

Phase 3

Daraxonrasib (RMC-6236)

Resectable pancreatic ductal adenocarcinoma

H2 2025

2/26/25- To initiate Ph3 trial in H2 2025.

Initiation

LSTA

Phase 1b/2a

LSTA1 + FOLFIRINOX (neoadjuvant) + panitumumab

Pancreatic, colon and appendiceal cancers

2025

CENDIFOX trial. 5/13/24- Full enrollment reached. Complete enrollment in 2 remaining cohorts by end of 2024. 12/10/24- Completed enrollment in CENDIFOX trial. Results in 2025.

Data Readout

ERAS

Phase 3

Naporafenib (pan-RAF inhibitor) w/ trametinib

NRASm melanoma

2025

SEACRAFT-2 trial. 6/18/24 - Ph1b/2 pooled data show favorable mOS and mPFS. Initiated Ph3 w/ data readout from stage 1 in 2025.

Data readout

MGNX

PDUFA

Retifanlimab (anti-PD-1 mAb)

NSCLC (Non-small cell lung carcinoma) and Anal Cancer

H2 2025

Drug is exclusively licensed to Incyte Corporation. Ph3 trial ongoing. 12/2024- sBLA for retifanlimab in advanced/metastatic SCAC filed, with approval anticipated in the second half of 2025.

Approval decision

NUVL

Phase 2

NVL-655

ALK-positive NSCLC (Non-small cell lung cancer)

2025

ALKOVE-1 Trial. 2/12/24- Initiated Ph2 portion. 9/14/24- Reported trail update at ESMO '24. Report pivotal trial data in 2025.

Data readout

MGNX

Phase 2

Lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) + docetaxel

Advanced solid tumors & mCRPC

H2 2025

LORIKEET study. Trial initiated. 5/9/24 Complete enrollment in 2024. 3/20/25- Clinical update in H2 2025.

Data readout

MRSN

Phase 1

Emiltatug Ledadotin (Emi-Le; XMT-1660)

Breast, endometrial and ovarian cancers

2025

8/13/24- Initial dose escalation (DE) and backfill cohort data. 1/10/25- Granted fast track designation. Enrollment expansion in H1 2025 for 67.4 mg/m2 Q4W. Initiate expansion enrollment for 2nd dose & present data from DE and backfill cohorts in 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20